GLP-1 and dual incretin agonists in obesity: 2025 state-of-the-art review
The Lancet Diabetes and Endocrinology
2025
Study summary
State-of-the-art review on GLP-1 and dual/triple incretin agonists in obesity treatment.
Peptides studied
Goals studied
Stack studied
Metabolic Stack
Advanced Metabolic Stack
Key findings
Semaglutide, tirzepatide, and next-generation agents were described as reshaping obesity care.
Study details
Study type
review article
Journal
The Lancet Diabetes and Endocrinology
DOI / PubMed
10.1016/S2213-8587(25)00091-2
Year
2025
Explore peptide profiles
Discover compounds, understand their mechanisms, and explore the research behind each peptide.